Current Status of Hypertension in China Cardiovascular Diseases in China - The Blue Book

Ge, Junbo; Huo, Yong; Zhang, Yanling; Han, Yaling; Yan, Hong‐Bin

doi:10.4103/2470-7511.248374

Cited by 7 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The abovementioned randomized studies were conducted a long time ago and do not reflect current clinical practices in China. The number of PCIs performed in China increased steadily from 2010 to 2018, with yearly increases ranging from 13.3% to 24.8% [17] and 914,256 PCIs performed in 2018. PCI has evolved considerably over the years with the development of technology and therapeutic modalities.…”

Section: Introductionmentioning

confidence: 99%

Incidence of Major Adverse Cardiovascular and Cerebrovascular Events in Chinese Patients Undergoing Percutaneous Coronary Intervention with Iodixanol: An Observational Postauthorization Study

Wang

et al. 2023

Cardiology Discovery

View full text Add to dashboard Cite

Objective: This study aimed to evaluate the major adverse cardiovascular and cerebrovascular events (MACCEs) and overall safety profile associated with iodixanol in Chinese patients undergoing percutaneous coronary intervention (PCI). Methods: Patients at 30 centers in China registered in the OpenClinic v3.6 database from October 30, 2013, to October 7, 2015, were included in the study. The primary endpoint was in-hospital MACCEs including target lesion revascularization (TLR), stroke, stent thrombosis, cardiac death, and PCI-related myocardial infarction (MI) within 72 h post-PCI. Secondary endpoints were MACCEs from 72 h to 30 d post-PCI and other safety events within 30 d post-PCI. Results: A total of 3,042 patients were enrolled. The incidence of MACCEs within 72 h post-PCI was 2.33% (n = 71), including cardiac death (0.03%, n = 1) and PCI-related MI (2.30%, n = 70). The incidence of MACCEs from 72 h to 30 d post-PCI was 0.16% (n = 5), including cardiac death (0.10%, n = 3), PCI-related MI (0.03%, n = 1), and TLR for stent thrombosis (0.03%, n = 1). The incidence of composite angiographic or procedural complications was 2.86% (n = 87); 233 (7.86%) patients had results suggesting contrast-induced acute kidney injury. Conclusions: These findings indicate that the use of iodixanol in Chinese patients undergoing PCI is associated with a low incidence of MACCEs, confirming its safety in this population.

show abstract

Section: Introductionmentioning

confidence: 99%

Incidence of Major Adverse Cardiovascular and Cerebrovascular Events in Chinese Patients Undergoing Percutaneous Coronary Intervention with Iodixanol: An Observational Postauthorization Study

Wang

et al. 2023

Cardiology Discovery

View full text Add to dashboard Cite

show abstract

Meta-Analysis of Gender Disparities in In-hospital Care and Outcomes in Patients with ST-Segment Elevation Myocardial Infarction

Shah

Haimi

Yang

et al. 2021

The American Journal of Cardiology

View full text Add to dashboard Cite

Cerebral microbleeds in patients with ischemic cerebrovascular disease taking aspirin or clopidogrel

Ge¹,

Ouyang

Ban³

et al. 2019

Medicine

View full text Add to dashboard Cite

Cerebral microbleeds (CMBs) may be markers of intracerebral bleeding risk in patients receiving antithrombotic drugs. This study aimed to analyze CMBs and white matter hyperintensities (WMHs) in patients taking aspirin or clopidogrel.This retrospective study included patients with ischemic cardiovascular disease administered 75 mg/day aspirin (n = 150) or clopidogrel (n = 150, matched for age and gender) for >1 year (Affiliated Hospital of Inner Mongolia Medical University, China, from July, 2010 to July, 2015). Patients underwent T2-weighted imaging, T1-weighted imaging, diffusion-weighted imaging (DWI) and enhanced T2∗-weighted angiography (ESWAN) imaging (3.0-Tesla scanner). Baseline vascular risk factors for CMBs and macroscopic bleeding (MB) were evaluated using univariate and multivariate analyses.The aspirin and clopidogrel groups did not differ significantly in baseline characteristics or prevalences of CMBs or MB. The odds of MB were higher in patients with CMBs than in patients without CMBs in both the aspirin (odds ratio, 95% confidence interval: 4.09, 1.93–8.68; P < .001) and clopidogrel (6.42, 2.83–14.57; P < .001) groups. The odds of WMHs were also higher in patients with CMBs in both the aspirin (3.28, 1.60–6.71; P = .001) and clopidogrel (4.09, 1.91–8.75; P < .001) groups. Patients receiving treatment for >5 years showed elevated risk of CMBs in the aspirin (0.17; 0.09–0.36; P < .001) and clopidogrel (0.15, 0.07–0.33; P < .001) groups as well as higher odds of MB in the aspirin (0.34, 0.16–0.71; P = .004) and clopidogrel (0.37, 0.17–0.80; P = .010) groups.The WMHs and MB were associated with CMBs in patients taking aspirin or clopidogrel for >1 year, and long-term use increased the risks of CMB and bleeding.

show abstract

Current Status of Hypertension in China Cardiovascular Diseases in China - The Blue Book

Cited by 7 publications

References 2 publications

Incidence of Major Adverse Cardiovascular and Cerebrovascular Events in Chinese Patients Undergoing Percutaneous Coronary Intervention with Iodixanol: An Observational Postauthorization Study

Incidence of Major Adverse Cardiovascular and Cerebrovascular Events in Chinese Patients Undergoing Percutaneous Coronary Intervention with Iodixanol: An Observational Postauthorization Study

Meta-Analysis of Gender Disparities in In-hospital Care and Outcomes in Patients with ST-Segment Elevation Myocardial Infarction

Cerebral microbleeds in patients with ischemic cerebrovascular disease taking aspirin or clopidogrel

Contact Info

Product

Resources

About